Dennis Ding
Stock Analyst at Jefferies
(3.98)
# 1,780
Out of 4,556 analysts
93
Total ratings
51.8%
Success rate
11.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KARD Kardigan | Initiated Coverage: Buy | $40 | $22.86 | +74.98% | 1 | Jul 13, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $40 | $30.15 | +32.67% | 5 | Jul 10, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $55 → $85 | $83.72 | +1.53% | 4 | Jul 7, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $36.55 | +9.44% | 1 | Jul 6, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $15 | $5.08 | +195.28% | 7 | Jun 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $125 | $103.97 | +20.23% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Maintained: Buy | $62 | $20.54 | +201.85% | 4 | May 19, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $19.30 | +13.99% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $11.49 | +248.13% | 1 | Mar 19, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $18 → $30 | $34.91 | -14.06% | 16 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $4.33 | +61.66% | 4 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $26 | $27.01 | -3.74% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $40.45 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $31.70 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $18 | $39.05 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $2.17 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $26.04 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $2.98 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $2.26 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $19.85 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $2.76 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $90.88 | n/a | 4 | Feb 14, 2023 |
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $22.86
Upside: +74.98%
Teva Pharmaceutical Industries
Jul 10, 2026
Maintained: Buy
Price Target: $40
Current: $30.15
Upside: +32.67%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: $55 → $85
Current: $83.72
Upside: +1.53%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $36.55
Upside: +9.44%
Ardelyx
Jun 26, 2026
Maintained: Buy
Price Target: $15
Current: $5.08
Upside: +195.28%
Rhythm Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $125
Current: $103.97
Upside: +20.23%
SpyGlass Pharma
May 19, 2026
Maintained: Buy
Price Target: $62
Current: $20.54
Upside: +201.85%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $19.30
Upside: +13.99%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $11.49
Upside: +248.13%
Roivant Sciences
Feb 9, 2026
Maintained: Buy
Price Target: $18 → $30
Current: $34.91
Upside: -14.06%
Dec 11, 2025
Maintained: Buy
Price Target: $7
Current: $4.33
Upside: +61.66%
Sep 3, 2025
Maintained: Hold
Price Target: $15 → $26
Current: $27.01
Upside: -3.74%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $40.45
Upside: n/a
Jun 11, 2025
Maintained: Buy
Price Target: $45
Current: $31.70
Upside: n/a
May 29, 2025
Maintained: Hold
Price Target: $20 → $18
Current: $39.05
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $2.17
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $26.04
Upside: n/a
Sep 3, 2024
Maintained: Hold
Price Target: $8 → $6
Current: $2.98
Upside: n/a
Jul 17, 2024
Maintained: Hold
Price Target: $1
Current: $2.26
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $19.85
Upside: n/a
Jul 13, 2023
Maintained: Buy
Price Target: $18
Current: $2.76
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $90.88
Upside: n/a